AYTU Stock Overview
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Aytu BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.79 |
| 52 Week High | US$3.50 |
| 52 Week Low | US$1.38 |
| Beta | -1.26 |
| 1 Month Change | -2.45% |
| 3 Month Change | 10.28% |
| 1 Year Change | 4.49% |
| 3 Year Change | -97.90% |
| 5 Year Change | -99.29% |
| Change since IPO | -100.00% |
Recent News & Updates
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results
Feb 17
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Feb 16Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
Jan 23Recent updates
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results
Feb 17Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Feb 16Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?
Jan 23Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too
Sep 29Aytu stock falls amid suspending clinical programs to save costs
Oct 13Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M
Sep 27Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder
Sep 14Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders
Aug 16Aytu BioPharma plunges on pricing $10M stock and warrants offering
Aug 09Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00
May 19Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?
Sep 11Aytu BioPharma up 21% in afternoon trading
Jun 21Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now
May 15A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation
Feb 14Aytu BioScience: Time To Call In The Cavalry Of Value Catalysts
Dec 31Aytu BioScience completes safety study in critically ill COVID-19 patients
Dec 28Aytu Bio raises 'bought deal' offering to $25M
Dec 11Aytu BioScience: The Barcode King Is Poised For An Epic Breakout
Nov 12Shareholder Returns
| AYTU | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -10.6% | -2.3% | -3.7% |
| 1Y | 4.5% | 11.4% | 20.2% |
Return vs Industry: AYTU underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: AYTU underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| AYTU volatility | |
|---|---|
| AYTU Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AYTU has not had significant price volatility in the past 3 months.
Volatility Over Time: AYTU's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 150 | Josh Disbrow | aytubio.com |
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.
Aytu BioPharma, Inc. Fundamentals Summary
| AYTU fundamental statistics | |
|---|---|
| Market cap | US$15.53m |
| Earnings (TTM) | -US$18.00m |
| Revenue (TTM) | US$98.50m |
0.2x
P/S Ratio-0.9x
P/E RatioIs AYTU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AYTU income statement (TTM) | |
|---|---|
| Revenue | US$98.50m |
| Cost of Revenue | US$36.20m |
| Gross Profit | US$62.29m |
| Other Expenses | US$80.29m |
| Earnings | -US$18.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.23 |
| Gross Margin | 63.24% |
| Net Profit Margin | -18.27% |
| Debt/Equity Ratio | 48.7% |
How did AYTU perform over the long term?
See historical performance and comparison